TRT and Androgenetic Alopecia: Does Testosterone Therapy Speed Up Hair Loss?

This explains a paradox well known from clinical practice: two men on an identical dose and form of testosterone, with very similar blood hormone levels, can have completely different fates when it comes to hair — one notices accelerated thinning within a few months, the other sees no change even after years of therapy. Below, we explain the mechanism behind this and what the latest genetic data from large population studies say on the subject.

Androgenetic alopecia isn't caused directly by testosterone, but by dihydrotestosterone (DHT) — a more potent androgen formed from testosterone by the enzyme 5-alpha-reductase, present in the dermal papilla cells at the base of the hair follicle. DHT binds the androgen receptor far more strongly than testosterone itself, and it's this DHT-receptor complex that, in genetically susceptible follicles, triggers miniaturization: successive hair growth cycles produce progressively shorter, less pigmented hairs (vellus hairs), until the follicle eventually stops producing a visible hair at all.

Crucially, 5-alpha-reductase activity and androgen receptor density aren't distributed evenly across the scalp. In the frontal and crown areas (typical of the male pattern) enzyme activity and receptor density are much higher than in the occipital (back-of-head) region — hence the classic, well-known pattern of a receding hairline and crown thinning, with a preserved band of hair at the back of the head, which is even used as a donor site in hair transplant procedures, since those follicles are relatively resistant to DHT regardless of its concentration.

This is the most important, and least intuitive, part of the mechanism: research indicates that susceptibility to androgenetic alopecia depends primarily on androgen receptor sensitivity and local 5-alpha-reductase activity in hair follicles, not on total circulating testosterone in the blood. Men with low, normal, and high testosterone levels can all equally develop androgenetic alopecia if they're genetically susceptible — and conversely, some men with high, even supraphysiological, testosterone levels never develop significant hair thinning if their androgen receptors are less sensitive.

Because genetics is the deciding factor rather than testosterone dose, the best practically available predictor of whether TRT will accelerate hair loss is family history and your current, baseline hair condition. Men whose father, maternal grandfather, or brothers had clear, early-onset male pattern baldness are statistically more likely to see that process accelerated by any therapy that increases androgen availability, including TRT — regardless of what dose or delivery form they choose.

Genetic tests specifically assessing CAG repeat length in the androgen receptor gene are commercially available, but their practical predictive value for a single patient is limited — the effect shown in population studies is statistically significant but small, and androgenetic alopecia is a polygenic trait influenced by many other loci, not just the androgen receptor alone. In clinical practice, documenting baseline hair condition, for example with photos taken before starting therapy, can be just as useful, sometimes more so, than a single genetic test.

A second, equally common myth claims the opposite: that androgenetic alopecia is an unavoidable consequence of TRT for every patient, which leads some men to delay a well-justified therapy decision out of fear, despite documented hypogonadism and real benefits from treating it. In reality, a significant share of men on long-term TRT notice no meaningful change in their hair at all — it depends on individual, genetically determined susceptibility, not on the fact of being on therapy itself.

The question „does TRT cause hair loss” is, fundamentally, the wrong question — the right one is „am I genetically susceptible to androgenetic alopecia, and if so, will TRT accelerate a process that would likely have happened to me anyway.” This distinction, confirmed by large genetic data from the UK Biobank, should change how men approach this worry before starting therapy — not as a dose-dependent lottery, but as a process whose risk can be reasonably estimated before the first injection, simply by looking at family history.